Emily Luisa Hill Sells 9,256 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 9,256 shares of Replimune Group stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at approximately $3,082,366.56. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56.

Replimune Group Stock Down 5.1%

Replimune Group stock opened at $14.05 on Friday. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.70. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -4.46 and a beta of 0.88. The firm’s fifty day moving average price is $11.13 and its two-hundred day moving average price is $8.00. The company has a current ratio of 5.23, a quick ratio of 4.79 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities research analysts predict that Replimune Group, Inc. will post -2.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Replimune Group from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. Finally, Wolfe Research upgraded Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Replimune Group presently has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Institutional Trading of Replimune Group

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Replimune Group in the 2nd quarter valued at $99,171,000. Balyasny Asset Management L.P. increased its position in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Replimune Group during the 4th quarter worth $17,568,000. Commodore Capital LP purchased a new position in shares of Replimune Group in the 4th quarter worth about $13,851,000. Finally, EcoR1 Capital LLC purchased a new position in shares of Replimune Group in the 1st quarter worth about $7,650,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.